Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Neoplasms 9Prostatic Neoplasms 6Multiple Myeloma 6Fractures, Bone 4Neoplasm Metastasis 3Giant Cell Tumor of Bone 3Carcinoma, Non-Small-Cell Lung 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Parathyroid Neoplasms 2Osteoporosis 2Lymphoma 2Thyroid Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Processes 1Neoplastic Cells, Circulating 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Hyperparathyroidism, Primary 1Hypercalcemia 1

Interventions

radium Ra 223 dichloride 1Everolimus 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone Refractory Prostate Cancer × Denosumab × Clear all
NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Amgen

Phase 3 Completed
1,435 enrolled 15 charts
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡